Aeon Biopharma News and Activities

Aeon Biopharma is a company listed under the stock ticker AEON (US).

View the org chart displaying its 9 main executives

Most searched biographies at Aeon Biopharma

• Rob Bancroft, President and Chief Executive Officer
• Shelley Thunen, Board Member
• Jost Fischer, Chairman of the Board

Popular executive movements at Aeon Biopharma

• Rob Bancroft will join the company as President and Chief Executive Officer on Apr. 29, 2025  (posted on April 22 2025).
• Jost Fischer who is Chairman of the Board, will become Chairman of the Board and Interim Chief Executive Officer on Apr. 4, 2025  (posted on April 1 2025).
• Marc Forth who is President, Chief Executive Officer and Director, will become Director on Apr. 4, 2025  (posted on April 1 2025).

Create your alert
to follow the executive moves at Aeon Biopharma.

Aeon Biopharma has 2,340 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).

Popular M&A news in Biotechnology

• Stylus Medicine has just announced a $85 Million fundraising (posted on May 16 2025).
• Azafaros has just announced a $132 Million fundraising (posted on May 15 2025).
• The new name of Garuda Therapeutics is Stratus Therapeutics. (posted on May 12 2025).

Popular contacts in Biotechnology

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Deepika Verma - Associate Director of Data Science and Digitalization at Wheeler Bio
• Steven Gillis - Chairman of the Board at VBI Vaccines

Learn more about the Biotechnology industry

Press releases by Aeon Biopharma

• AEON Biopharma - Investors - News
• AEON Biopharma - AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
• AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
• AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
• Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma
• AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
• AEON Biopharma to Host Key Opinion Leader Webinar on Past, Present, and Potential Future Treatments for Migraine on February 24th
• AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination
• AEON Biopharma Confirms Development Strategy and Timelines for ABP-450 Unaffected by Korean Court Ruling on Dispute Between Medytox and Daewoong Pharmaceutical
• Activating the full potential of therapeutic botulinum toxin | AEON Biopharma
• View more press releases Close

Social media about Aeon Biopharma

• Aeon Biopharma on Wikipedia, Google News & Yahoo Finance
• Aeon Biopharma on LinkedIn, Twitter & YouTube